Cargando…
Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the r...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917796/ https://www.ncbi.nlm.nih.gov/pubmed/26991794 http://dx.doi.org/10.1111/bcp.12938 |
_version_ | 1782438999530405888 |
---|---|
author | Donati, Monia Conforti, Anita Lenti, Maria Carmela Capuano, Annalisa Bortolami, Oscar Motola, Domenico Moretti, Ugo Vannacci, Alfredo Rafaniello, Concetta Vaccheri, Alberto Arzenton, Elena Bonaiuti, Roberto Sportiello, Liberata Leone, Roberto |
author_facet | Donati, Monia Conforti, Anita Lenti, Maria Carmela Capuano, Annalisa Bortolami, Oscar Motola, Domenico Moretti, Ugo Vannacci, Alfredo Rafaniello, Concetta Vaccheri, Alberto Arzenton, Elena Bonaiuti, Roberto Sportiello, Liberata Leone, Roberto |
author_sort | Donati, Monia |
collection | PubMed |
description | AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. METHODS: This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. RESULTS: We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00). CONCLUSION: Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity. |
format | Online Article Text |
id | pubmed-4917796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49177962016-11-04 Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy Donati, Monia Conforti, Anita Lenti, Maria Carmela Capuano, Annalisa Bortolami, Oscar Motola, Domenico Moretti, Ugo Vannacci, Alfredo Rafaniello, Concetta Vaccheri, Alberto Arzenton, Elena Bonaiuti, Roberto Sportiello, Liberata Leone, Roberto Br J Clin Pharmacol Pharmacoepidemiology AIM: Drug‐induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti‐inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. METHODS: This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. RESULTS: We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00). CONCLUSION: Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity. John Wiley and Sons Inc. 2016-04-27 2016-07 /pmc/articles/PMC4917796/ /pubmed/26991794 http://dx.doi.org/10.1111/bcp.12938 Text en © 2016 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Pharmacoepidemiology Donati, Monia Conforti, Anita Lenti, Maria Carmela Capuano, Annalisa Bortolami, Oscar Motola, Domenico Moretti, Ugo Vannacci, Alfredo Rafaniello, Concetta Vaccheri, Alberto Arzenton, Elena Bonaiuti, Roberto Sportiello, Liberata Leone, Roberto Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title | Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title_full | Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title_fullStr | Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title_full_unstemmed | Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title_short | Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy |
title_sort | risk of acute and serious liver injury associated to nimesulide and other nsaids: data from drug‐induced liver injury case–control study in italy |
topic | Pharmacoepidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917796/ https://www.ncbi.nlm.nih.gov/pubmed/26991794 http://dx.doi.org/10.1111/bcp.12938 |
work_keys_str_mv | AT donatimonia riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT confortianita riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT lentimariacarmela riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT capuanoannalisa riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT bortolamioscar riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT motoladomenico riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT morettiugo riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT vannaccialfredo riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT rafanielloconcetta riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT vaccherialberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT arzentonelena riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT bonaiutiroberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT sportielloliberata riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT leoneroberto riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly AT riskofacuteandseriousliverinjuryassociatedtonimesulideandothernsaidsdatafromdruginducedliverinjurycasecontrolstudyinitaly |